14-methyl-20-oxa-5-7-14-26-tetraazatetracyclo(19.3.1.1(2-6).1(8-12))heptacosa-1(25)-2(26)-3-5-8(27)-9-11-16-21-23-decaene has been researched along with Brain-Neoplasms* in 2 studies
2 other study(ies) available for 14-methyl-20-oxa-5-7-14-26-tetraazatetracyclo(19.3.1.1(2-6).1(8-12))heptacosa-1(25)-2(26)-3-5-8(27)-9-11-16-21-23-decaene and Brain-Neoplasms
| Article | Year |
|---|---|
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
TG02 is a novel cyclin-dependent kinase (CDK) inhibitor and thought to act mainly via CDK-9 inhibition-dependent depletion of short-lived oncoproteins such as MCL-1 or c-MYC. We studied the activity of TG02 in 9 human long-term glioma cell lines (LTC) and 5 glioma-initiating cell lines (GIC) using various cell death assays in vitro and in the LN-229 LTC and ZH-161 GIC models in vivo. TG02 exhibits strong anti-tumor cell activity with EC Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Gene Expression; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; RNA, Messenger; Tissue Distribution; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Energy Metabolism; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Mice, Inbred C57BL; Temozolomide; Transcription, Genetic | 2018 |